Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
Sapna Pradyuman PatelMegan OthusYuanbin ChenG Paul WrightKathleen J YostJohn R HyngstromSiwen Hu-LieskovanChristopher D LaoLeslie A FecherThach-Giao TruongJennifer L EisensteinSunandana ChandraJeffrey A SosmanKari L KendraRichard C WuCraig E DevoeGary B DeutschAparna HegdeMaya KhalilAnkit ManglaAmy M ReeseMerrick I RossAndrew S PoklepovicGiao Q PhanAdedayo A OnitiloDemet G YasarBenjamin C PowersGary C DoolittleGino K InNiels KokotGeoffrey T GibneyMichael B AtkinsMontaser ShaheenJames A WarnekeAlexandra IkeguchiJose E NajeraBartosz ChmielowskiJoseph G CromptonJustin D FloydEddy HsuehKim A MargolinWarren A ChowKenneth F GrossmannEliana DietrichVictor G PrietoMichael C LoweElizabeth I BuchbinderJohn M KirkwoodLarissa KordeJames MoonElad SharonVernon K SondakAntoni RibasPublished in: The New England journal of medicine (2023)
Among patients with resectable stage III or IV melanoma, event-free survival was significantly longer among those who received pembrolizumab both before and after surgery than among those who received adjuvant pembrolizumab alone. No new toxic effects were identified. (Funded by the National Cancer Institute and Merck Sharp and Dohme; S1801 ClinicalTrials.gov number, NCT03698019.).